A Randomized, Double-Blinded, Sham-Controlled Trial of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 4
- 试验地点
- 4
- 主要终点
- Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) Post Treatment 30 or Last Treatment (in the Case of Early Withdrawal)
研究概览
简要总结
This research proposal aims to better understand the neurobiology of depression in adolescents and how repetitive transcranial magnetic stimulation (rTMS) may therapeutically impact brain function and mood. This investigation also proposes the first study to examine the efficacy of rTMS maintenance therapy in adolescents who have met clinical criteria following acute rTMS treatment. The magnetic resonance (MR) spectroscopy pattern of rTMS response will be analyzed according to previously established protocols.
详细描述
Part 2 of the study aims to:
-
Evaluate the benefit of daily, active, open-label rTMS in Part 1 non-responders.
-
Evaluate the benefits of bi-weekly, active, open-label maintenance rTMS treatment for Part 1 responders over the course of 12 months post acute treatment.
-
Evaluate, by proton magnetic resonance spectroscopy (1H-MRS) at 3 Tesla(3T), neurometabolic biomarkers at the beginning and end of each study phase.
-
Define regional specificity [anterior cingulate (AC) and left dorsolateral prefrontal cortex (L-DLPFC)] of cerebral metabolites (i.e. glutamate and glutamine) in adolescent depression.
-
Study whether specific neurochemical resonances are associated with response, remission, and/or maintenance of improvement of clinical depressive symptoms when rTMS is used to treat adolescent depression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Successful completion of Part 1 of study
- •Diagnosis of unipolar major depressive disorder, in a current major depressive episode, without psychotic features
- •Age is at least 12 and less than 22 years
- •Ongoing, stable dose antidepressant therapy for at least 6 weeks to include the following antidepressants (with dosing range):
- •Celexa (citalopram hydrobromide) - 10 to 60mg
- •Cymbalta (duloxetine) - 40mg to 120mg
- •Desyrel (trazodone HCl) - 12.5mg to 150mg
- •Effexor (venlafaxine HCl) - 37.5mg to 300mg
- •Luvox (fluvoxamine maleate) - 25mg to 200mg
- •Lexapro (escitalopram oxalate) - 10mg to 40mg
- •Paxil (paroxetine HCl) - 10mg to 50mg
- •Pristiq (desvenlafaxine) - 50mg to 100mg
- •Prozac (fluoxetine HCl) - 10mg to 80mg
- •Remeron (mirtazapine) - 7.5mg to 45mg
- •Savella (milnacipran HCl) - 25mg to 200mg
- •Zoloft (sertraline HCl) - 25mg to 200mg
- •Subjects able to attend all study visits at study site.
- •Willing to provide informed assent (adolescent) and informed consent (family)
排除标准
- •Withdrew from treatment of study Part 1
- •Subjects currently on stimulant, antipsychotic, bupropion or tricyclic antidepressant medications.
- •Prior vagus nerve stimulation (VNS) or electroconvulsive therapy (ECT)
- •Contraindication to MRI
- •Contraindication to rTMS (history of neurological disorder such as seizures, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for >15 minutes, history of stroke, family history of epilepsy, intracardiac lines, Anticoagulant, immune suppressive and/or chemotherapy, or those who received any of these therapies within 3 months before enrollment in the study Unstable medication conditions such as hematological or infectious (e.g., human immunodeficiency virus-HIV) disorders, implanted electronic device, metal in the head, or pregnancy)
- •History of schizophrenia, schizoaffective disorder, other [non mood disorder] psychosis, depression secondary to a medical condition, mental retardation, substance dependence or abuse within the past year (except nicotine), bipolar disorder, psychotic features in this or previous episodes, amnestic disorder, obsessive compulsive disorder, post-traumatic stress disorder, panic disorder
- •History of autoimmune, endocrine, viral, or vascular disorder.
- •Unstable cardiac disease, uncontrolled hypertension, or sleep apnea
- •Active suicidal intent or plan, or history of attempt within the past 6 months
结局指标
主要结局
Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) Post Treatment 30 or Last Treatment (in the Case of Early Withdrawal)
时间窗: Within 5 days after Treatment 30 or Last Treatment
The Clinical Global Impression - Severity (CGI-S) is a standardized assessment utilizing a 7-point scale with which the clinician rates the severity of the subject's depressive illness at the time of assessment relative to the clinician's past experience with patients who have the same diagnosis.
Mean Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Post Treatment 30 or Last Treatment (in the Case of Early Withdrawal)
时间窗: Within 5 days after Treatment 30 or Last Treatment
The Children's Depression Rating Scale-Revised (CDRS-R) is a validated, 17-item, semi-structured clinician rating tool to assess severity of depression with subject and parental input for 14 of the 17 items.
Mean Clinical Global Impression - Improvement (CGI-I) Score Post Treatment 30 or Last Treatment (in the Case of Early Withdrawal)
时间窗: Within 5 days after Treatment 30 or Last Treatment
The Clinical Global Impression - Improvement (CGI-I) is a standardized assessment utilizing a 7-point scale with which the clinician rates the degree to which the severity of the subject's depressive illness has improved or worsened compared to baseline severity.
次要结局
未报告次要终点
研究者
Paul E. Croarkin
Assistant Professor of Child and Adolescent Psychiatry
Mayo Clinic